Austràlia - anglès - APVMA (Australian Pesticides and Veterinary Medicines Authority)

syngenta australia pty ltd - prosulfocarb - emulsifiable concentrate - prosulfocarb carbamate-thiocarbamate active 800.0 g/l - herbicide

Estats Units - anglès - NLM (National Library of Medicine)

plum valley pharma llc - indications gel sheeting is intended for use in the management, control, and prevention of old and new hypertrophic or keloid scars resulting from burns or surgical or traumatic injury of the skin. contraindications do not use on open wounds or when any dermatological conditions disrupt the skin (such as a rash). instructions for use silicone gel sheeting - wash both scar and hands per cleaning instructions. - open the non-sterile pouch containing the silicone gel sheet. - clear gel sheeting is covered on both sides by a plastic film. fabric gel sheeting is covered on the tacky side by a plastic film. remove plastic film prior to use. - the gel sheet may be cut into smaller pieces using scissors or a scalpel. once you have determined the appropriate size of sheeting to use, apply tacky side to the scar. the gel sheeting should fully cover the scar and extend ¼ inch all the way around the scar border. - the exposed surface of the gel sheeting may be covered wi

Estats Units - anglès - NLM (National Library of Medicine)

aralez pharmaceuticals us inc. - aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9) - aspirin 81 mg - yosprala, a combination of aspirin and omeprazole, is indicated for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. the aspirin component of yosprala is indicated for: - reducing the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli, - reducing the combined risk of death and nonfatal mi in patients with a previous mi or unstable angina pectoris, - reducing the combined risk of mi and sudden death in patients with chronic stable angina pectoris, - use in patients who have undergone revascularization procedures (coronary artery bypass graft [cabg] or percutaneous transluminal coronary angioplasty [ptca]) when there is a pre-existing condition for which aspirin is already indicated. the omeprazole component of yosprala is indicated for decreasing the risk of developing aspirin-associated gastric u

Estats Units - anglès - NLM (National Library of Medicine)

aralez pharmaceuticals us inc. - vorapaxar sulfate (unii: in66038e6c) (vorapaxar - unii:zce93644n2) - vorapaxar 2.08 mg - zontivity ® is indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (mi) or with peripheral arterial disease (pad). zontivity has been shown to reduce the rate of a combined endpoint of cardiovascular death, mi, stroke, and urgent coronary revascularization (ucr). zontivity is contraindicated in patients with a history of stroke, tia, or ich because of an increased risk of ich in this population [see adverse reactions (6)] . discontinue zontivity in patients who experience a stroke, tia, or ich [see adverse reactions (6.1) and clinical studies (14)] . zontivity is contraindicated in patients with active pathological bleeding such as ich or peptic ulcer [see warnings and precautions (5.1) and adverse reactions (6.1)] . risk summary based on the potenti

Canadà - anglès - Health Canada

sanofi-synthelabo canada inc - chloroquine phosphate - tablet - 250mg - chloroquine phosphate 250mg - antimalarials

Canadà - anglès - Health Canada

aralez pharmaceuticals canada inc - acetylsalicylic acid; caffeine; butalbital; codeine phosphate - capsule - 330mg; 40mg; 50mg; 15mg - acetylsalicylic acid 330mg; caffeine 40mg; butalbital 50mg; codeine phosphate 15mg - opiate agonists

Canadà - anglès - Health Canada

aralez pharmaceuticals canada inc - butalbital; caffeine; acetylsalicylic acid - capsule - 50mg; 40mg; 330mg - butalbital 50mg; caffeine 40mg; acetylsalicylic acid 330mg - barbiturates

Canadà - anglès - Health Canada

aralez pharmaceuticals canada inc - diclofenac potassium - powder for solution - 50mg - diclofenac potassium 50mg - other nonsteroidal antiimflammatory agents

Estats Units - anglès - NLM (National Library of Medicine)

aralez pharmaceuticals us inc. - fenofibric acid (unii: bgf9mn2hu1) (fenofibric acid - unii:bgf9mn2hu1) - fenofibric acid 35 mg - fibricor is indicated as adjunctive therapy to diet for treatment of severe hypertriglyceridemia (≥ 500 mg/dl). improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention. markedly elevated levels of serum triglycerides > 2000 mg/dl may increase the risk of developing pancreatitis. the effect of fenofibrate therapy on reducing this risk has not been adequately studied. fibricor is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (ldl-c), total cholesterol (total-c), triglycerides (tg), and apolipoprotein b (apo b), and to increase high-density lipoprotein cholesterol (hdl-c) in patients with primary hypercholesterolemia or mixed dyslipidemia. fenofibrate at a dose equivalent to 105 mg of fibricor was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus [see warnings and precautions (5.1) ]. fibricor is contraindicated in: - pat

Canadà - anglès - Health Canada

aralez pharmaceuticals canada inc - sumatriptan (sumatriptan succinate); naproxen sodium - tablet - 85mg; 500mg - sumatriptan (sumatriptan succinate) 85mg; naproxen sodium 500mg - other nonsteroidal antiimflammatory agents